Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05695248 · ClinicalTrials.gov registry record · Phase 1

A Study of STAR-0215 in Participants With Hereditary Angioedema

A Phase 1 study of Hereditary Angioedema, sponsored by Astria Therapeutics.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
20
Study locations

NCT05695248 is a Phase 1 study of Hereditary Angioedema that has completed, run by Astria Therapeutics. The registered enrollment target is 29 participants, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05695248, a Phase 1 study of Hereditary Angioedema, has completed, sponsored by Astria Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

Conditions Studied

Hereditary Angioedema

Interventions

  • DRUG STAR-0215

Study Locations (20)

Other

  • Diagnostical Consultative Center Convex Ltd. - Sofia
  • Institute of Clinical Immunology/Allergology, Faculty Hospital - Hradec Králové
  • Charité Universitätsmedizin Berlin - Berlin
  • Addenbrooke's Hospital - Cambridge
  • St. James's Hospital - Leeds

California

  • UC San Diego US HAEA Angioedema Center - San Diego
  • Raffi Tachdjian MD, Inc - Santa Monica
  • Allergy & Asthma Clinical Research - Walnut Creek

Arkansas

  • Allergy & Asthma Clinic of Northwest Arkansas - Bentonville
  • Acuro Research, Inc. - Little Rock

Alabama

  • Allervie Clinical Research - Birmingham

Arizona

  • Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD. - Scottsdale

Maryland

  • Institute for Asthma and Allergy, PC - Chevy Chase

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2023-02-21
Est. Completion 2025-03-13
Phase Phase 1

Sponsor

Astria Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05695248

The ClinicalTrials.gov registry entry for NCT05695248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (61% lower). The listed sponsor is Astria Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which STAR-0215 is the first listed.

NCT05695248 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT05695248 about?

NCT05695248 is a clinical study titled "A Study of STAR-0215 in Participants With Hereditary Angioedema". The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this...

What is the current status of trial NCT05695248?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-02-21. Estimated completion is 2025-03-13.

What conditions does trial NCT05695248 study?

This clinical trial studies the following conditions: Hereditary Angioedema.

What interventions are being tested in trial NCT05695248?

The interventions under investigation include: STAR-0215 (DRUG).

Who is sponsoring clinical trial NCT05695248?

This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05695248 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hereditary Angioedema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hereditary Angioedema

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.